Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Overview
3. Background and molecular classification in EC
4. Endometrial cancer
5. Treatment for recurrent/metastatic EC
6. Risk stratification in early-stage
7. Risk stratification in early-stage disease
8. Risk stratification- molecular classification
9. Categorising “double classifiers”
10. Other considerations regarding the importance of biomarker testing
11. Biomarker testing in the era of molecular classifications: Focus on dMMR
12. MLH1 promotor hypermethylation and Lynch testing
13. Risk stratification
14. Molecular classification as prognostic marker
15. Molecular classification as a prognostic marker for EC
16. Prognostic classification of EC using NGS panel
17. ProMisE molecular classifier
18. ProMisE outcomes
19. Molecular-based classification of EC
20. Prognostic value of molecular classification
21. L1CAM expression in high-risk EC
22. Molecular classification as prognostic marker and implications
23. Molecular classification as predictive marker
24. PORTEC 3
25. PORTEC 3 – molecular markers
26. RUBY trial
27. RUBY – outcomes
28. KEYNOTE-868/ NRG-GY018
29. KEYNOTE-868 - PFS
30. DUO-E trial
31. DUO-E trial –dMMR
32. pMMR biomarker-known subpopulation
33. pMMR subpopulation: CP + durvalumab vs. CP
34. pMMR subpopulation: CP + durvalumab + Olaparib vs. CP
35. Phase 3 randomised, double-blind study
36. Immunotherapy in dMMR patients: Evidence from the adjuvant setting
37. Hormonal therapy
38. Prognostic impact of molecular classification in fertility-sparing treatment
39. Molecular classification predicts radiotherapy response
40. GOG-258 outcomes according to ProMiSE
41. Molecular classification as predictive marker & treatment response
42. Integrating molecular classification into clinical practice
43. Essential clinical requirements
44. British Association of Gynaecological Pathologists guidance on POLE testing
45. ESGO/ESTRO/ESP guidelines for patients with EC
46. 2023 FIGO staging of cancer of the endometrium (1)
47. Future pathways
48. 2023 FIGO staging of cancer of the endometrium (2)
49. RAINBO trial
50. Potential future pathway – IO single agent
51. DOMENICA trial
52. Future treatment pathways
53. Thank you and financial disclosures

Topics Covered

• Background and molecular classification in endometrial cancer
• Molecular classification as prognostic marker
• Molecular classification as predictive marker for treatment response
• Integrating molecular classification into clinical practice
• Future pathways

Links

Series:

• Periodic Reports: Advances in Clinical Interventions and Research Platforms

Categories:

• Cancer
• Cell Biology
• Clinical Practice

Therapeutic Areas:

• Gynaecology & Obstetrics
• Oncology

Talk Citation

Eminowicz, G. (2025, October 30). Endometrial cancer: integrating molecular insights into personalized care [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 30, 2025, from https://doi.org/10.69645/XEPR2964.
Export Citation (RIS)

Publication History

• Published on October 30, 2025

Financial Disclosures

• Dr. Gemma Eminowicz has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.